Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non-Current Assets (2021 - 2025)

Verrica Pharmaceuticals has reported Other Non-Current Assets over the past 5 years, most recently at $376000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $376000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $376000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $376000.0, changed 0.0%.
  • Other Non-Current Assets for Q4 2025 was $376000.0 at Verrica Pharmaceuticals, roughly flat from $376000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for VRCA hit a ceiling of $40.0 million in Q1 2022 and a floor of $221000.0 in Q3 2022.
  • Median Other Non-Current Assets over the past 5 years was $376000.0 (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 4123.86% in 2022 and later tumbled 99.08% in 2023.
  • Verrica Pharmaceuticals' Other Non-Current Assets stood at $295000.0 in 2021, then fell by 6.44% to $276000.0 in 2022, then surged by 63.77% to $452000.0 in 2023, then fell by 16.81% to $376000.0 in 2024, then changed by 0.0% to $376000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $376000.0 (Q4 2025), $376000.0 (Q3 2025), and $376000.0 (Q2 2025) per Business Quant data.